Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 50fludarabine phosphate 47Busulfan 46Cyclosporine 36Antilymphocyte Serum 33Cytarabine 32Peripheral Blood Stem Cell Transplantation 30Radiotherapy 28Filgrastim 27Methotrexate 23Melphalan 23Mycophenolic Acid 21Cord Blood Stem Cell Transplantation 21Methylprednisolone 20Etoposide 17Whole-Body Irradiation 16Tacrolimus 15Daunorubicin 11Epoetin Alfa 10fludarabine 9Thiotepa 9Alemtuzumab 8Idarubicin 7Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Mitoxantrone 6Azacitidine 6Arsenic Trioxide 6Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × 7-hydroxystaurosporine × Classical hematology × Clear all
NCT00004263 2012-07-30

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡